Search This Blog

Monday, October 5, 2026

Genmab reports positive Phase 3 in newly diagnosed DLBCL

 

Genmab reports positive Phase 3 EPCORE DLBCL-2 results as epcoritamab plus R-CHOP significantly improves PFS in newly diagnosed DLBCL

  • Genmab and AbbVie plan to engage global regulators on next steps following EPCORE DLBCL-2 topline results.
  • ADC rinatabart sesutecan shows durable, clinically meaningful responses in Phase 2 RAINFOL-01 trial for platinum-resistant ovarian cancer.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)